Journal
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
Volume 405, Issue 30, Pages 9779-9789Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00216-013-7419-7
Keywords
Xylazine; Metabolism; Human; Detectability; Gas chromatography-mass spectrometry; Liquid chromatography-multistage mass spectrometry; Liquid chromatography-high-resolution multistage mass spectrometry
Ask authors/readers for more resources
Xylazine is used in veterinary medicine for sedation, anesthesia, and analgesia. It has also been reported to be misused as a horse doping agent, a drug of abuse, a drug for attempted sexual assault, and as source of accidental or intended poisonings. So far, no data concerning human metabolism have been described. Such data are necessary for the development of toxicological detection methods for monitoring drug abuse, as in most cases the metabolites are the analytical targets. Therefore, the metabolism of xylazine was investigated in rat and human urine after several sample workup procedures. The metabolites were identified using gas chromatography (GC)-mass spectrometry (MS) and liquid chromatography (LC) coupled with linear ion trap high-resolution multistage MS (MS (n) ). Xylazine was N-dealkylated and S-dealkylated, oxidized, and/or hydroxylated to 12 phase I metabolites. The phenolic metabolites were partly excreted as glucuronides or sulfates. All phase I and phase II metabolites identified in rat urine were also detected in human urine. In rat urine after a low dose as well as in human urine after an overdose, mainly the hydroxy metabolites were detected using the authors' standard urine screening approaches by GC-MS and LC-MS (n) . Thus, it should be possible to monitor application of xylazine assuming similar toxicokinetics in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available